PROMACTA is a prescription medicine. PROMACTA is used to treat blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) aplastic anemia.
INDICATIONS AND USAGE
PROMACTA is a thrombopoietin receptor agonist indicated for the treatment of:
• thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
• thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.
• patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
DOSAGE FORMS & STRENGTHS
• Tablets: 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg
• For oral suspension: 25 mg
Manufactured By: GlaxoSmithKline
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “PROMACTA (eltrombopag) for oral suspension” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Eltrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. Designated an orphan drug in the United States and European Union, it is being manufactured and marketed by Novartis under the trade name Promacta in the US and is marketed as Revolade in the EU. Novartis acquired the drug as a part of its asset swap deal with GlaxoSmithKline.